National Cholesterol Education Program, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda, Md National Institutes of Health, National Heart, Lung, and Blood Institute1993;Publication 93-3095
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA.
1993;2693015- 3023Link to Article
TR Lipoproteins, cardiovascular disease, and death: the Framingham Study. Arch Intern Med.
1981;1411128- 1131Link to Article
WB Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA.
1986;2562835- 2838Link to Article
D Serum cholesterol, blood pressure, and mortality: implication from a cohort of 361,662 men. Lancet.
1986;2933- 936Link to Article
et al. Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA.
1994;271999- 1003Link to Article
PM Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med.
1971;741- 12Link to Article
et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol.
1986;81245- 1255Link to Article
Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA.
1984;251351- 364Link to Article
et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med.
1987;3171237- 1245Link to Article
HJ The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications [editorial]. Am J Cardiol.
1993;721072- 1073Link to Article
The Pravastatin Multinational Study Group for Cardiac Risk Patients, Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol.
1993;721031- 1037Link to Article
Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial Results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA.
1984;251365- 374Link to Article
Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;3441383- 1389
et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet.
1992;339563- 569Link to Article
MEPLAC I and PLAC II Investigators, Reduction in coronary events during treatment with pravastatin. Am J Cardiol.
1995;7660C- 63CLink to Article
et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol.
1995;75455- 459Link to Article
et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med.
1995;3331301- 1307Link to Article
et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med.
1994;1541586- 1595Link to Article
et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.
1993;119969- 976Link to Article
et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med.
1990;3231289- 1298Link to Article
RJ Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA.
1990;2643007- 3012Link to Article
et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation.
1984;69313- 324Link to Article
MA Pravastatin, lipids, and major coronary events. Am J Cardiol.
1994;731133- 1134Link to Article
L Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA.
1987;2573233- 3240Link to Article
et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med.
1990;323946- 955Link to Article
SA The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA.
1995;2731032- 1038Link to Article
et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA.
1993;2693002- 3008Link to Article
et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA.
1993;2693009- 3014Link to Article
J A new method of estimating cost-effectiveness of cholesterol reduction therapy for prevention of heart disease. Pharmacoeconomics.
1994;5238- 248Link to Article
The Asilomar Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature, Checklist of information for inclusion in reports of clinical trials. Ann Intern Med.
1996;124741- 743Link to Article
SM Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med.
1995;155393- 399Link to Article
L Efficacy and safety of choletyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr.
1996;12942- 49Link to Article
SM Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short term, double blind, crossover trial. Ann Intern Med. 1994;21416- 422
Not Available, Simvastatin (Zocor) [package insert]. West Point, Pa Merck & Co Inc1995;
et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med.
1994;120537- 543Link to Article
et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol.
1994;46445- 449Link to Article
A Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. Med J Aust. 1992;157584- 589
et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. Am J Med.
1991;90469- 473Link to Article
B Treatment of patients with elevated plasma levels of low-density lipoproteins with a cholestyramine tablet compared with cholestyramine powder. Curr Ther Res.
1992;52330- 336Link to Article
et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol.
1992;70135- 140Link to Article
et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med.
1995;123493- 499Link to Article
Ose L Low dose colestipol in adolescents with familial hypercholesterolemia. Arch Dis Child.
1996;74157- 160Link to Article
JC Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol.
1994;3759- 62Link to Article
et al. Efficacy and safety of once-daily vs twice-daily dosing fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med.
1994;1542449- 2455Link to Article
Sandoz Pharmaceuticals Corp, Fluvastatin Study No. 24: Multicenter Double-blind Crossover Study of the Safety, Bioavailability, and Efficacy of Fluvastatin Administered 20 mg Once a Day at Bedtime or With the Evening Meal. Hanover, NJ Sandoz-Pharmaceuticals Corp1994;
Sandoz Pharmaceuticals Corp, Fluvastatin Study No. 22: Multicenter Double-blind Evaluation of the Safety and Contribution to the Efficacy of Concomitant Fluvastatin and Open-Label Cholestyramine. Hanover, NJ Sandoz Pharmaceuticals Corp1994;
Sandoz Pharmaceuticals Corp, Fluvastatin Study No. 41: Evaluation of the Safety and Efficacy of Fluvastatin With and Without Concomitant Open-Label Niacin. Hanover, NJ Sandoz Pharmaceuticals Corp1994;
MH Fluvastatin Long-term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med.
1994;96(suppl 6A)41S- 44SLink to Article
LF Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol.
1994;7325D- 29DLink to Article
LF Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med.
1994;96(suppl 6A)64S- 68SLink to Article
Sandoz Pharmaceuticals Corp, Fluvastatin Study No. 20: Multicenter Double-blind Evaluation of the Safety and Efficacy of Fluvastatin. Hanover, NJ Sandoz Pharmaceuticals Corp1994;
JM Fluvastatin reduces levels of plasma apo B–containing particles and increases those of LpA-I. Am J Med.
1994;96(suppl 6A)32S- 36SLink to Article
E Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. Am J Cardiol.
1994;7330D- 38DLink to Article
D Comparative dose efficacy study atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol.
1998;81582- 587Link to Article
DW Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination. Am J Cardiol.
1995;76126A- 128ALink to Article
BI Fluvastatin for dyslipo-proteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol.
1995;7697A- 101ALink to Article
G Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. Am J Cardiol.
1995;7651A- 53ALink to Article
M Long-term treatment of hypercholesterolemia with fluvastatin: a 52 week multicenter safety and efficacy study, French-Dutch Fluvastatin Study Group. Am J Med.
1994;9687S- 93SLink to Article
D Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med.
1994;9669S- 78SLink to Article
M Fluvastatin in primary hypercholesterolemia—efficacy and safety in patients at high risk: an analysis of a clinical trial database. Am J Med.
1994;9679S- 83SLink to Article
et al. Treatment of primary hypercholesterolemia: fluvastatin versus benzafibrate. Am J Med.
1994;96(suppl 6A)55S- 63SLink to Article
Not Available, Lovastatin (Mevacor) [package insert]. West Point, Pa Merck & Co Inc1995;
M Cholesterol-lowering effects of 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dL (5.18 to 6.21 mmol/liter). Am J Cardiol.
1991;681123- 1126Link to Article
SM Hypercholesterolemia in postmenopausal women: metabolic defects and response to low-dose lovastatin. JAMA.
1994;271453- 459Link to Article
Sandoz Pharmaceuticals Corp, Fluvastatin Study No. 21. Hanover, NJ Sandoz Pharmaceuticals Corp1994;
et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther. 1992;14276- 291
The Lovastatin-Pravastatin Study Group, A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol.
1993;71810- 815Link to Article
G Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther. 1992;14708- 717
et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med.
1993;118850- 855Link to Article
P Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoprotein. Int J Tissue React. 1991;13107- 110
GJ Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis.
1992;9653- 64Link to Article
et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol.
1995;7534- 39Link to Article
JL Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets. JAMA.
1991;265997- 1001Link to Article
Lovastatin Study Groups I through IV, Lovastatin 5-year safety and efficacy study. Arch Intern Med.
1993;1531079- 1087Link to Article
VM A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA.
1994;271672- 677Link to Article
CM Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med.
1991;1511424- 1432Link to Article
et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol.
1994;73339- 345Link to Article
JD Once-daily pravastatin in patients with primary hypercholesterolemia: a dose response study. Clin Cardiol.
1991;14146- 151Link to Article
The Simvastatin-Pravastatin Study Group, Comparison of the efficacy, safety, and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol.
1993;711408- 1414Link to Article
B Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia. Clin Ther. 1991;13500- 510
E Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia: Simvastatin-Pravastatin European Study Group. Cardiology.
1994;85244- 254Link to Article
European Study Group, Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol.
1992;701281- 1286Link to Article
E Pravastatin and risk factor modification in patients with moderate primary hypercholesterolemia. N Z Med J. 1996;109319- 322
KB A comparison of estrogen replacement, pravastatin and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med.
1997;1371186- 1192Link to Article
MEuropean Study Group, Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolaemia. Drug Invest.
1993;6353- 361Link to Article
PLEuropean Study Group, Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol. 1993;48541- 554
Not Available, Pravastatin (Pravachol) [package insert]. New York, NY Bristol-Myers Squibb Co1995;
et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med.
1993;9413- 20Link to Article
J Treating hypercholesterolaemia with HMG-CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Aust N Z J Med.
1993;23381- 386Link to Article
H Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron.
1994;6857- 62Link to Article
U Prediction of therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol.
1994;46107- 114Link to Article
A Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med.
1994;154441- 449Link to Article
Not Available, Fluvastatin (Lescol) [package insert]. East Hanover, NJ Sandoz Pharmaceuticals Corp1995;
DW Combination drug therapy with HMG-CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology.
1990;77(suppl 4)33- 38Link to Article
A Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust. 1992;157455- 459
G Combination drug therapy for hypercholesterolemia: the trade-off between cost and simplicity. Arch Intern Med.
1993;1531828- 1837Link to Article
Not Available, Colestipol (Colestid) [package insert]. Kalamazoo, Mich Pharmacia & Upjohn Co1994;
PA Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary disease. JAMA.
1991;2651145- 1151Link to Article
Not Available, Cholesterol management and practice guidelines at Kaiser Permanente Southern California: designing prevention programs—from research to reality. Med Interface. 1993;69- 14
CD Cholesterol reduction yields clinical benefit: a new look at old data. Circulation.
1995;912274- 2282Link to Article
et al. Treatment of primary hypercholesterolaemia—short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. J Intern Med.
1993;23477- 82Link to Article
D Treatment of hyperlipidemia in women. JAMA.
1995;2741152- 1158Link to Article
et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis.
1997;130191- 197Link to Article